Petition To Restrict St. John’s Wort Draws Fire From Industry
This article was originally published in The Tan Sheet
Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.
You may also be interested in...
Bayer buys herbal firm; NBTY notes bright spots, hires international leader; Neptune prepares to rebuild; P&G suit targets CAO’s tooth whiteners; CSPI supports restricting St. John’s wort; Coppertone schools parents; Hillary Clinton will speak at NACDS Total Store Expo.
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
St. John's wort is more effective at treating major depressive disorder (MDD) than fluoxetine (Eli Lilly's Prozac), according to a study published in the October Journal of Clinical Psychopharmacology.